UK MHRA grants marketing approval for Ipsen’s elafibranor to treat adults with rare liver disease known as PCB: United Kingdom Thursday, October 10, 2024, 15:00 Hrs [IST] The Me ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved elafibranor (Iqirvo) to treat adult patients with a rare type of liver disease known as primary biliary cholangitis ...
Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has conditionally approved Iqirvo ® (elafibranor) 80mg tablets for the treatment of primary biliary cholangitis (PBC) in ...
Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In ...
The European Commission has granted conditional approval for Ipsen's IQIRVO (elafibranor) for the treatment of primary biliary cholangitis in adults, marking the first new therapy for this condition ...